valproic acid has been researched along with Hypertension, Pulmonary in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male Sprague-Dawley rats were injected with a single, subcutaneous dose of monocrotaline (60 mg/kg), and were exposed to chronic hypoxia to induce severe PH." | 7.81 | Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension. ( Furutani, Y; Hayama, E; Kawaguchi, N; Lan, B; Nakanishi, T, 2015) |
| " Both valproic acid, a class I HDAC inhibitor, and suberoylanilide hydroxamic acid (vorinostat), an inhibitor of class I, II, and IV HDACs, mitigated the development of and reduced established hypoxia-induced pulmonary hypertension in the rat." | 7.78 | Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. ( Chen, CN; Cotroneo, E; Hajji, N; Li, M; McKinsey, TA; Oliver, E; Stenmark, KR; Wang, D; Wharton, J; Wilkins, MR; Zhao, L, 2012) |
| "Male Sprague-Dawley rats were injected with a single, subcutaneous dose of monocrotaline (60 mg/kg), and were exposed to chronic hypoxia to induce severe PH." | 3.81 | Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension. ( Furutani, Y; Hayama, E; Kawaguchi, N; Lan, B; Nakanishi, T, 2015) |
| " Both valproic acid, a class I HDAC inhibitor, and suberoylanilide hydroxamic acid (vorinostat), an inhibitor of class I, II, and IV HDACs, mitigated the development of and reduced established hypoxia-induced pulmonary hypertension in the rat." | 3.78 | Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. ( Chen, CN; Cotroneo, E; Hajji, N; Li, M; McKinsey, TA; Oliver, E; Stenmark, KR; Wang, D; Wharton, J; Wilkins, MR; Zhao, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogaard, HJ | 2 |
| Mizuno, S | 2 |
| Voelkel, NF | 2 |
| Zhao, L | 2 |
| Chen, CN | 2 |
| Hajji, N | 2 |
| Oliver, E | 2 |
| Cotroneo, E | 2 |
| Wharton, J | 2 |
| Wilkins, MR | 2 |
| Wang, D | 2 |
| Li, M | 2 |
| Stenmark, KR | 2 |
| McKinsey, TA | 2 |
| Buttrick, P | 1 |
| Lan, B | 1 |
| Hayama, E | 1 |
| Kawaguchi, N | 1 |
| Furutani, Y | 1 |
| Nakanishi, T | 1 |
| Hussaini, AA | 1 |
| Toldo, S | 1 |
| Abbate, A | 1 |
| Kraskauskas, D | 1 |
| Kasper, M | 1 |
| Natarajan, R | 1 |
5 other studies available for valproic acid and Hypertension, Pulmonary
| Article | Year |
|---|---|
Letter by Bogaard et al regarding article, "histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid".
Topics: Animals; Histone Deacetylases; Humans; Hydroxamic Acids; Hypertension, Pulmonary; Male; Valproic Aci | 2013 |
Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.
Topics: Animals; Histone Deacetylases; Humans; Hydroxamic Acids; Hypertension, Pulmonary; Male; Valproic Aci | 2013 |
Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
Topics: Animals; Blood Pressure; Disease Models, Animal; Hemodynamics; Histone Deacetylase Inhibitors; Hyper | 2015 |
Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats.
Topics: Angiopoietin-1; Animals; Blotting, Western; Cells, Cultured; Disease Models, Animal; Dose-Response R | 2011 |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Topics: Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Histone Deacetylase 1; Histone | 2012 |